Free Trial
NASDAQ:ANNX

Annexon Q1 2025 Earnings Report

Annexon logo
$1.64 -0.17 (-9.12%)
Closing price 04:00 PM Eastern
Extended Trading
$1.74 +0.09 (+5.71%)
As of 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annexon EPS Results

Actual EPS
N/A
Consensus EPS
-$0.30
Beat/Miss
N/A
One Year Ago EPS
N/A

Annexon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Annexon Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
12:30PM ET

Conference Call Resources

Annexon Earnings Headlines

REVEALED: Elon’s Secret Master Plan “AGENDA X”
REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secret. Now, leaked computer code confirms Elon is moments away from launching a revolutionary financial technology… And Silicon Valley insider Jeff Brown says it could hand early investors who missed Tesla, "the ultimate second chance" to get rich.
See More Annexon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Annexon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annexon and other key companies, straight to your email.

About Annexon

Annexon (NASDAQ:ANNX), a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

View Annexon Profile

More Earnings Resources from MarketBeat